A clinical study in Guinea-Bissau testing the timing of the hepatitis B vaccine dose given at birth has become the latest flashpoint in the transatlantic argument over vaccine policy. The trial — paused amid controversy, now moving toward restart after a Danish university’s ethics approval on October 7 — has drawn pointed criticism from scientists including Dr. Colette Delawalla of the advocacy group Stand Up for Science, who have questioned whether the study should proceed at all.
The scientific question underneath the dispute is genuine. Hepatitis B vaccination at birth is global standard practice, timed to interrupt transmission from mother to child; researchers who study dosing schedules argue that comparing timing regimens in a high-burden setting produces evidence the world needs. Critics answer that where a proven intervention exists, withholding or delaying it in any study arm crosses an ethical line — and that findings from such a trial could be used to unsettle vaccination policy in countries where the debate is anything but academic.
That last fear is what gives a protocol dispute its political charge. In the United States, the hepatitis B birth dose has recently been contested territory, and both camps in the Guinea-Bissau argument understand that a study conducted in West Africa will be read as evidence in arguments happening in Washington. Supporters of the restart point to the ethics approval as the system working: independent review, in the country where the research occurs, judged the protocol acceptable. Opponents respond that approval is a floor, not a vindication.
The positions attributed to the critics, including Delawalla’s organisation, emphasise consent, equipoise and the vulnerability of newborn participants; the positions attributed to the study’s defenders emphasise local burden of disease and the legitimacy of Danish and Guinean review processes. Between those poles sits a question research ethics has never fully settled: who decides what a community’s children may be asked to test?
The trial will now proceed or not through the institutions that govern it. But the argument it started has already travelled further than the study ever will — into the widening global contest over what vaccine science is for, and who it answers to.
Related reading: A New Option After Surgery: FDA Backs Tecentriq Combination for a High-Risk Colon Cancer · CDC Data Trace a Rare Brain Fungus Moving the Wrong Way · A Year of NAD Boosters, and Parkinson's Did Not Budge
